Development and validation of a humanized mouse psoriasis model to be applied for efficacy analysis of novel therapeutic compounds

Completed

• Conditions: Flaking disease; Psoriasis; 10014982

• Registration Number: NL-OMON41218
• Lead Sponsor: TNO Triskelion

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 6

Inclusion Criteria

Adult Psoriasis patients, m/f, with a mild to moderate form of psoriasis vulgaris, i.e. a maximal PASI score of 18 and a minimum BSA of 3%. Patients are allowed to use local corticosteroids or ointments to prevent dry skin (see Appendix 2).

Exclusion Criteria

Psoriasis patients have NOT received light therapy or another form of SYSTEMIC treatment (e.g. treatment with methotrexate, cyclosporin A or anti-TNF). Gender or age of the adult patients are no exclusion criteria (see Appendix 2).

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>After finalization of the validation study, the transplanted biopsies are<br /><br>isolated to study the psoriatic process via histological techniques. The<br /><br>primary read-out is epidermal thickness.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>After finalization of the validation study, the transplanted biopsies are<br /><br>isolated to study the psoriatic process via histological techniques. The<br /><br>secundary read-out is proliferation and differentiation of cells in the skin.<br /><br>Moreover, the activation and differentiation status of immune cells will be<br /><br>determined in the blood of the donors.</p><br>